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Summary
 Background Irradiation of salivary glands during the treatment of head and neck cancer may 
lead to an alteration in the amount of saliva produced. Because of this, patients 
can suffer dryness of the mouth with oral discomfort, taste disturbance and den-
tal decay.
 Aim The aim of this study is to estimate late toxicity dependence on radiotherapy 
method. The main goal is to investigate the correlations between the radiation 
doses in salivary glands and their salivary excretion fractions (SEF) measured by 
dynamic scintigraphy.
 Materials/Methods In 40 patients with pharyngeal and laryngeal cancer irradiated by IMRT or con-
formal 3D to a total dose of 62.5–72.0Gy, parotid SEFs were measured. Parotid 
dose-volume histograms were obtained from 3D computer treatment planning. 
SEF measurements were performed before (baseline), and 6 weeks and 6 months 
after radiotherapy by 185MBq 99 Tc injected intravenously and next SEF rates 
were analysed in relation to radiation doses accumulated. The late radiation tox-
icity of salivary glands was tested according to the CTC v. 3.0 and SOMA-LENT 
scales. The non-parametric Mann Whitney test was used for the estimation of re-
lationships.
 Results Pre- and post-treatment SEFs were measured in 31 patients treated by IMRT and 
in 9 patients treated by 3D CRT. Six weeks after radiotherapy SEF was generally 
lower by 34%, and 6 months after irradiation by 29.3% in IMRT technique. In 
3D CRT relatively it was lower: after 6 weeks by average 52% and after 6 months 
by 35.5%. Late radiation toxicity of salivary glands was observed at a similar lev-
el according to CTC and SOMA-LENT scales in both methods of radiotherapy.
 Conclusions The level of SEF in parotid glands measured 6 weeks after radiotherapy clearly 
reﬂ ects the dose-response relationship of irradiated salivary tissue; 6 months lat-
er changes of SEF are the result of partial recovery of parotids.
  The results of sparing salivary glands can be optimized in the future; that is, a 
further reduction of xerostomia can be achieved by using improved IMRT tech-
niques and focusing on sparing major and minor salivary glands.
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BACKGROUND
Irradiation of salivary glands during the treatment 
of head and neck cancer may lead to an altera-
tion in the amount of saliva produced. Because 
of this, patients can suffer dryness of the mouth 
with oral discomfort, taste disturbance and den-
tal decay [1].
The salivary glands produce over a litre of saliva 
per day [2]. Ninety percent of salivary secretion 
is produced by major glands like the parotids, 
submandibular and sublingual glands; the rest of 
the saliva is produced by numerous minor salivary 
glands of the oral cavity [3]. The parotid and sub-
mandibular glands are the main contributors to 
salivary secretion; others produce only 2–5% of 
total salivary ﬂ ow [2] or salivary excretion frac-
tion (SEF) [4–6]. Under resting conditions the 
ﬂ ow from the submandibular glands is at least as 
great as that from the parotids, but after stimu-
lation (for instance eating) the parotids are the 
main contributors [1,7]. Parotids produce main-
ly serous acini saliva but submandibular and sub-
lingual glands produce both mucous and serous 
acini saliva. [1–3]. The serous acini are consid-
ered to be the most sensitive to ionising radiation 
[1,8], and the loss of the water part in secretion 
results in xerostomia during and after irradiation 
[1], specially when both parotid glands are in-
cluded in the treatment volume [8]. It should be 
noted that supportive treatment such as mouth 
rinses, saliva substitutes, salivary stimulants and 
often water consumption are generally ineffec-
tive and often not tolerated by patients [6].
To determine salivary gland function after radi-
otherapy, several methods have been employed. 
The most frequent are scoring systems such as 
SOMA-LENT [9–11], CTC [12] based on clin-
ical examination or different xerostomic ques-
tionnaires [6], visual analogue scales (VASs) and 
salivary scintigraphy [6,13]. Although xerostom-
ic questionnaires and scoring systems are wide-
ly used, their contribution is limited to informa-
tion about patients’ subjective feeling of dryness. 
Salivary ﬂ ow had usually been studied by meas-
uring saliva production using sialometry, but it is 
difﬁ cult to determine the function of each gland 
separately [6]. Salivary scintigraphy after 99Tc ad-
ministration has been used to assess semi-quan-
titatively the excretion function of parotids and 
submandibular glands and correlates well with 
major salivary gland ﬂ ow rates [14], thus facili-
tating post-radiotherapy follow-up.
Moderate to severe xerostomia may be prevent-
ed in most patients using a conformal-sparing ra-
diotherapy technique [15]. IMRT might reduce 
the radiation dose to the major salivary glands, 
so the risk of permanent xerostomia can also be 
reduced. Alternatively, IMRT might allow target 
dose escalation at a given level of normal tissue 
damage.
AIM
We describe here the results of scintigraphy as 
an objective method to assess postirradiation sal-
ivary gland function. Also we have analysed the 
intensity of SEF reduction in head and neck can-
cer patients treated with IMRT and convention-
ally fractionated radiotherapy 3D CRT.
MATERIALS AND METHODS
Forty patients with squamous cell pharyngeal 
and laryngeal cancer were treated by radiother-
apy to a total dose of 62.5–72Gy in the First 
Radiotherapy Clinic at the Centre of Oncology 
– Maria Sklodowska-Curie Institute in Gliwice, 
between March 2004 and November 2006. All 
patients were irradiated in an accelerated regi-
men: 7 fractions weekly without weekend break 
(CAIR), concomitant boost (CB) – 7 fractions 
from Monday to Friday with boost on Tuesday and 
Friday, or 5 fractions in 5 days (from Monday to 
Friday) with fraction dose of 2.5Gy (patients with 
glottic cancer only). A decision to use IMRT was 
made in those cases where the use of 3D confor-
mal radiotherapy technique would have result-
ed in irradiation of all major salivary glands to a 
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cumulative dose greater than 45Gy with a high 
risk of subsequent post-irradiation xerostomia.
Pretreatment staging of the tumours was done by 
clinical examination, CT/MRI, endoscopy and bi-
opsies taken from the primary tumour. The tu-
mours were staged according to tumour-node-me-
tastasis (TNM) classiﬁ cation version 1997 [16]. 
All patients were treated on 6 MV photon line-
ar accelerator beams. The gross tumour volume 
(GTV) was determined by clinical examination, 
endoscopy, MRI or CT. GTV was included in the 
clinical target volume (CTV), where radiothera-
py was conducted to 54Gy in an accelerated reg-
imen or to 45Gy in fractionation with 2.5Gy in 
glottic cancer patients. A 3 mm margin was add-
ed to the CTVs to obtain the planning target vol-
ume (PTV). This margin was selected based on 
the set-up accuracy measurements performed 
with the localisation of the tumour. The dose 
uniformity criteria inside the PTV were deﬁ ned 
according to ICRU 50 [17].
The organs at risk (OAR) were deﬁ ned on all 
treatment planning CT slices. Typically, the OARs 
included the spinal cord, the brain stem, the sal-
ivary glands and mandibular bone. The salivary 
glands treated as OAR included both parotid 
glands and often both submandibular glands. 
The decision how to spare parotids depended on 
the presence of lymph node metastases and the 
predicted risk of malignant subclinical disease. 
Sparing of the contralateral submandibular gland 
was attempted only in cases where the primary tu-
mour did not cross the midline and no contralat-
eral metastases were known to be present.
The salivary excretion fraction (SEF) was assessed 
before therapy (the baseline values – SEF0) and 
6 weeks and 6 months after completion of radio-
therapy, by 185MBq 99 Tc injected intravenously. 
Pre- and post-treatment SEFs were measured for 
62 parotids irradiated respectively in 31 patients 
by IMRT and for 11 patients treated by 3D CRT. 
SEF rates were analysed in relation to radiation 
doses. SEF was measured after inserting diluted 
lemon juice into the dorsal part of linguae.
Following irradiation the patients were exam-
ined by a team of the First Radiotherapy Clinic 
with two otorhinolaryngologists within clinical 
examination and endoscopy: 3 months after ir-
radiation and every six months to 30 months af-
ter ﬁ nishing treatment. Late radiation toxicity of 
salivary glands was scored by CTC criteria v. 3.0 
and SOMA-LENT scale (Table 1).
Statistical methods
Non-parametric Mann-Whitney test was used 
for the estimation of relationships between 
treatment techniques (IMRT vs 3D CRT). The 
Characteristic N (%)
Gender
 Female  11 (27.5)
 Male  29 (72.5)
Site
 Oropharynx  9 (22.5)
 Hypopharynx  6 (15.0)
 Larynx: supraglottic  14 (35.0)
  glottic  11 (27.5)
Tumour size
 T2  29 (72.5)
 T3  5 (12.5)
 T4  6 (15.0)
Nodal status
 N0  23 (57.5)
 N1  10 (25.0)
 N2  6 (15.0)
 Nx  1 (2.5)
Radiotherapy (Gy/fractions/
days)
62.5/ 2.5/ 25  11 (27.5)
68.4/ 1.8/ 38  8 (20.0)
70.2/ 1.8/ 39  6 (15.0)
72.0/ 1.8/ 40  15 (37.5)
Accelerated radiotherapy 
(scheme regimen)
 CAIR  20 (50.0)
 CB  9 (22.5)
Radiotherapy
 IMRT  31 (77.5)
 3D  9 (22.5)
Age
 Mean 56.03
 Range 40–70
Table 1. Patient, tumour characteristic and dose prescription.
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statistical signiﬁ cance of differences in param-
eter ΔF (ΔF = SEF post RT – SEF0/SEF0) [4] at 
less and greater than the dose thresholds was 
tested using the two-sided Mann-Whitney rank-
sum test.
RESULTS
The mean radiation dose to the parotids in ana-
lysed material was 33.8Gy.
The mean, median and modal doses to parot-
id glands, and also their irradiated volume de-
pendence on radiotherapy regimen, are detailed 
in Table 2.
Scintigraphy results
For the change in the relative saliva excretion 
rate before and after treatment, the reduction 
was observed for the two analysed groups’ de-
pendence on radiotherapy technique regimen. 
Six weeks after radiotherapy SEFs were general-
ly lower on average by 34%, 6 months after on 
average by 29.3% for patients treated by IMRT. 
There was observed a higher reduction for pa-
tients treated by 3D CRT – six weeks after radio-
therapy SEFs were lower on average by 52% and 
6 months after on average by 35.5% – but this 
was not statistically signiﬁ cant.
These differences were observed only for abso-
lute values (Table 2).
For the change in the relative excretion rate, ΔF, 
a reduction was observed for all analysed groups 
(Figure 1 represents the change of relative excretion 
rate after 6 weeks and Figure 2 – after 6 months). 
A comparison of ΔF for doses less than and greater 
than the deﬁ ned dose thresholds yielded statistically 
signiﬁ cant differences for the parotid glands.
The SEF ratio was used to evaluate the percent-
age of SEF lost after RT (6 weeks and 6 months) 
with respect to the baseline SEF0. Nine patients 
(18 parotids) underwent scintigraphy before 6 
weeks and 6 months after radiotherapy in 3D 
CRT technique. In the IMRT group 30 patients 
(60 parotids) underwent scintigraphy before 6 
weeks and 20 patients (40 parotids) in 6 months 
after radiotherapy. The reduction in excretion was 
dependent on the parotid gland dose. There was 
no signiﬁ cant correlation between the 6-week and 
6-month post-RT ratios and the pre-RT excretion 
fractions and the mean dose in IMRT technique 
(Figure 3), and also in 3D CRT (Figure 4).
Late radiation toxicity results
The late radiation toxicity of salivary glands was 
scored according to CTC version 3.0 criteria every 6 
months to 30 months of follow-up. The intensity of 
late radiation reaction for both IMRT and 3D CRT 
techniques was very similar (Figure 5). According to 
the SOMA-LENT scale there was also observed very 
good concordance of the intensity of late reaction 
in the whole time of observation (Figure 6).
Radiotherapy technique N (parotids) Mean (%) Confi dence interval –95% Confi dence interval +95%
IMRT
SEF 6 weeks/ 0 weeks 60  33.96 21.95 45.98
SEF 6 months/ 0 weeks 40  29.32 18.46 40.18
Mean dose (Gy) 62  33.82
Median dose (Gy) 62  34.0
Modal dose (Gy) 62  36.31
Irradiated volume (cm3) 62  19.03
3D CRT
SEF 6 weeks/ 0 weeks 18  51.91 36.13 67.68
SEF 6 months/ 0 weeks 18  35.56 13.93 57.18
Mean dose (Gy) 18  34.61
Median dose (Gy) 18  33.27
Modal dose (Gy) 18  35.1
Irradiated volume (cm3) 18  24.4
Table 2. The change of relative saliva before and after irradiation dependence on radiotherapy technique.
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DISCUSSION
In the treatment of head and neck cancer by ra-
diotherapy the major salivary glands are often 
included in the irradiated volume. Tumour site, 
stage and the need for nodal irradiation will de-
termine which salivary glands are included. The 
risk of dryness can be reduced if during treatment 
planning volume of salivary tissue irradiated can 
be minimised [1,18]. If only submandibular and 
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Figure 1. The change of relative excretion rate after 6 weeks.
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Figure 2. The change of relative excretion rate after 6 months.
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Figure 3. The change of SEF value after 6 weeks and 6 months 
post RT in the relation to mean dose in IMRT technique.
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sublingual glands can be spared within the treat-
ment volume and both parotids are outside the 
radiation volume included, most patients note 
little or no difference in the quantity and char-
acter of saliva [1]. Although the minor salivary 
glands have only limited contribution to the basal 
or the stimulated saliva ﬂ ow rates, preservation 
of their function is also of importance, because 
the minor salivary glands produce up to 70% of 
the total mucin secreted by salivary glands. [19]. 
Mira et al. [20] suggest that it is necessary to ex-
clude more than 50% of both parotids from the 
treatment volume to prevent severe dryness. It is 
also important to avoid oral cavity and oropha-
ryngeal mucosa when possible [21].
There are a number of ways to increase the effec-
tiveness of radiation in cancer of the head and 
neck. During the past decade altered fractiona-
tion and various combinations have been clini-
cally tested [22–27]. Finally, 3D CRT and IMRT 
are means which allow application of high doses 
of radiation through minimising toxicity [28–30]. 
Braaksma et al. [31] described the optimisation 
of conformal radiotherapy by intensity modu-
lation for laryngeal cancer patients only with a 
high percentage of T1-T2 glottic irradiated to a 
total dose of 70Gy, where it was possible to ex-
clude one parotid. The results of Saarilathi et al. 
have suggested that much of salivary gland func-
tion can be maintained with IMRT [21]. They 
described the treatment technique: in addition 
to the OARs, a volume of healthy tissue was de-
lineated outside the PTV for dose optimisation. 
This technique has been found to be efﬁ cient in 
minimizing the risk of hot spots outside the PTV. 
Eisbruch et al. showed that in addition to the ma-
jor salivary glands, sparing the non-involved oral 
cavity should be considered as a planning objec-
tive to further reduce xerostomia [32].
In our material with high stages of tumour and 
nodal metastases all patients were irradiated to 
both sides of the neck with similar dryness in both 
techniques (IMRT and 3D CRT) according to 
CTC and SOMA-LENT scales. Also the oral cavity 
and oropharyngeal mucosal membrane were not 
always avoided in our planning. However, scin-
tigraphy, which was used as an objective method 
to assess toxicity, demonstrated lower reduction 
of SEFs in IMRT than in 3D CRT.
M.D. Leslie and S. Dische have described parot-
id gland function following accelerated CHART 
(54Gy in 36 fractions over 12 consecutive days) 
and conventionally fractionated radiotherapy. 
Following CHART, there was less impairment of 
parotid gland function as compared with that 
after conventionally radiotherapy to doses of 
60–66Gy. This has conﬁ rmed their clinical im-
pression that following CHART to squamous cell 
cancer in the head and neck there was less than 
expected dryness of the mouth [33]. The better 
function of the parotid gland following CHART 
was connected with the much lower total dose of 
35–40Gy in comparison to the total dose of 60–
66Gy fractionated conventionally [18]. In our 
study all patients were treated in an accelerated 
way, but with no reduction of total dose; thus the 
accumulated dose within the parotids was much 
higher than in the CHART study.
Scintigraphic methods continue to play a role in 
the study of functional disorders [34]. They are 
able to detect minor impairment of glandular func-
tion. The parotid glands may be imaged and their 
function assessed using technetium. The scan can 
supply additional features by following changes in 
the excretion function of the parotid glands. In 
our study parotid gland function was assessed by 
scintigraphy with technetium before radiotherapy, 
and early (6 weeks) and later (6 months) after ﬁ n-
ishing irradiation. Later changes, after 6 months, 
in SEFs have shown partial recovery in parotids 
better in IMRT technique than in 3D CRT. These 
results associating partial recovery of parotids with 
time after treatment are in correlation with oth-
ers. For example, Cha et al. registered a recovery 
of about 50% of secretory function after irradia-
tion with 60Gy during 5 to 8 months after ﬁ nish-
ing radiotherapy [35]. Roesink observed some 
recovery of function of parotids at 1 year after ra-
diotherapy in scintigraphy assessment [5].
CONCLUSIONS
The amount of SEF in parotid glands measured 
6 weeks after radiotherapy clearly reﬂ ects the 
dose-response relationship of irradiated salivary 
tissue. 6 months later changes of SEFs are an in-
dication of partial recovery of parotids.
The results of sparing salivary glands can be op-
timised in the future; that is, a further reduction 
of xerostomia can be achieved by using improved 
IMRT techniques and focusing on sparing major 
and minor salivary glands.
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